SunRock Biopharma and Chime Biologics Announce Strategic Collaboration to Advance Development of Anti-CCR9 Antibody SRB5

0
33
SunRock Biopharma and Chime Biologics announced a strategic collaboration for the development of SRB5, a novel anti-CCR9 monoclonal antibody targeting IBD.
[SunRock Biopharma]
Press Release